查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842112

全球下一代癌症诊断市场：市场规模、份额和趋势分析（按技术、应用、癌症类型、功能和地区划分），细分市场预测（2025-2033 年）

Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays), By Application, By Cancer Type, By Function, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 138 Pages | 商品交期: 2-10个工作天内

价格

下一代癌症诊断：市场概览

全球下一代癌症诊断市场预计到 2024 年将达到 166.1 亿美元，到 2033 年将达到 414.4 亿美元，2025 年至 2033 年的复合年增长率为 11.15%。

预计该行业的成长将受到以下因素的推动：肿瘤疾病的日益普遍、对各种癌症进行有效预后和早期诊断的需求，以及主要企业为满足日益增长的高效诊断需求而开发创新解决方案的倡议。

传统上，癌症诊断涉及多项检查，包括身体检查、实验室影像检查和切片检查。常规诊断流程的每一步，以及肿瘤科医师所做的预后和治疗方法决策，都遵循一套明确的流程以避免潜在的併发症。这凸显了诊断在肿瘤治疗整个生命週期中的关键作用，其重要性甚至超过了治疗方法。

次世代定序(NGS) 已成为肿瘤诊断领域的变革性力量，能够对肿瘤进行全面的基因组分析，并将患者与标靶治疗相匹配。透过识别可操作的突变和分子改变，NGS 支持个人化医疗策略，从而改善临床疗效。然而，定序在常规诊疗中的作用仍需更清晰的证据分层，因为并非所有携带可操作突变的患者最终都能接受标靶治疗。诸如诊疗流程中定序时机的选择、医生解读、定序的可及性有限以及成本效益等障碍，仍然限制着定序技术的更广泛应用。

诸如TAPUR研究和NCI MATCH研究等大型倡议旨在产生关于定序序列主导的治疗选择影响的可靠真实世界证据。儘管美国医疗保险和医疗补助服务中心（CMS）的国家医疗保险覆盖范围决定（NCDC）透过核准FoundationOne CDx（F1CDx）等检测扩大了医疗服务的可及性，但取消「基于证据开发的申请」要求引发了人们对持续追踪治疗结果的呼吁，包括总生存期、无恶化生存期和缓解率等指标。批评者认为，更全面的检测组合（如F1CDx）可能会增加成本，但未必能带来相应的临床获益，NCI MATCH研究中某些标靶治疗组的缓解率较低就证明了这一点。这凸显了对基于序列定序的治疗方法进行更多循证检验的必要性。

除了基因组学之外，该领域正迅速向多体学整合发展。 DNA 提供了一个静态的蓝图，而 RNA 定序（转录组学）和蛋白质组学（质谱分析）等互补方法则提供了基因表现和蛋白质讯号路径动态变化的见解。结合代谢体学，这些资料层能够描绘出肿瘤生物学的整体情况图像。诸如 TCGA 之类的计划凸显了整合体学的潜力，但如何将这些数据集整合为具有临床指导意义的结果仍然面临挑战。

同时，各公司正加速这些技术的临床应用。 2025年5月，Illumina公司推出了TruSight Oncology (TSO) Comprehensive试剂盒，进一步拓展了其肿瘤产品组合。该套件是首个获得FDA核准的、可商用的CGP体外诊断试剂套件，具备泛癌伴随诊断（CDx）功能，目前已纳入Medicare和大多数商业保险的报销范围。该检测涵盖500多个基因，并已获得日本监管机构的核准，目前正在社区医院和学术中心进行临床应用。 Illumina公司也深化了与Pillar Biosciences公司的合作，将oncoReveal® CDx panel添加到MiSeq Dx系统中，进一步普及了自体肿瘤基因谱分析。同样，2025年6月，QIAGEN和Incyte公司启动合作，共同开发用于骨髓增生性肿瘤的多模态NGS伴随诊断试剂盒。此检测可检测 mutCALR 突变，并支持 Incyte 公司针对原发性血小板增多症和骨髓纤维化的创新抗体计画 (INCA033989)。 2025 年 3 月，GenomOncology 与 Chronetyx Laboratories 合作，透过整合其病理工作台软体与 Chronetyx 已获 FDA已通过核准、CE-IVD 认证的 Cyx Solid Tumor 505 检测，简化临床应用流程，实现三级分析自动化，并显着缩短 NGS 结果的周转时间。这些倡议共同凸显了领导企业如何解决报销、工作流程自动化和生物标记扩展的瓶颈，从而加速精准肿瘤学的普及应用。

二代定序（NGS）在肿瘤免疫诊断中也扮演核心角色。肿瘤突变负荷（TMB）、PD-L1表现和新抗原谱分析正日益被用作免疫查核点抑制剂疗效的生物标记。晚期肝细胞癌（HCC）的证据表明，TP53突变与存活期延长有关，而TERT和BRD4突变则预示着预后不良。EXOME显子序列测定和蛋白质体学的结合有助于识别主要组织相容性复合体（MHC）呈现的新抗原，指南个别化免疫治疗策略。

液态切片和单细胞定序等新兴诊断方法正在进一步塑造市场格局。液态切片能够非侵入性检测循环肿瘤DNA（ctDNA），并即时监测治疗抗药性；而单细胞定序能揭示肿瘤内异质性，并识别可能驱动抗药性和转移的亚克隆。这些技术共同克服了传统组织切片检查的关键局限性，并有望加速精准肿瘤学的普及应用。

人工智慧 (AI) 和机器学习 (ML) 的融合是推动这些进步的重要因素。这些工具能够分析大量大量的大量定序 (NGS) 和多组体学资料集，并揭示隐藏的关联性，从而为预测建模、治疗选择和抗药性机制的研究提供资讯。人工智慧增强的生物资讯流程有望提高诊断准确性、缩短週转时间并优化临床决策，使其成为下一代癌症诊断市场的关键成长驱动力。

然而，仍有许多挑战。并非所有检测到的突变都具有临床意义，许多突变处于灰色地带，其临床效用尚不清楚。围绕着意外发现、患者知情同意和资料隐私等伦理问题，进一步增加了技术应用的复杂性。标准化指南、更完善的证据框架以及肿瘤学家、遗传学家、生物资讯学家和伦理学家之间的多学科合作，对于充分发挥新一代定序（NGS）及相关技术的潜力至关重要。

整体而言，市场正从单一模式的基因组分析朝向整合的、人工智慧驱动的多组体学解决方案演进。 Illumina公司获得FDA核准的CGP检测、QIAGEN公司专注于血液学的伴随诊断以及GenomOncology公司的工作流程自动化伙伴关係进展，加上液态切片和免疫肿瘤生物标誌物的广泛应用，为该领域的显着增长奠定了基础。然而，其长期发展轨迹将取决于能否在真实临床环境中展现出明确的临床效用、成本效益以及改善患者预后的效果。

目录

第一章：下一代癌症诊断市场：分析方法和范围

第二章：下一代癌症诊断市场：执行摘要

  • 市场概述
  • 技术与应用：简介
  • 癌症类型和功能：概览
  • 竞争格局概览

第三章：下一代癌症诊断市场：驱动因素、趋势和范围

  • 市场区隔及范围
  • 市场关联性展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素分析
    • 基因定序的成本正在呈指数级下降。
    • 丛集晶片技术的发展及其在癌症治疗的潜在应用
    • 对预防医学和伴随诊断的需求日益增长
    • 癌症发生率增加
  • 市场限制因素分析
    • 需要昂贵的实验室设备来进行新的测试
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章：下一代癌症诊断市场：按技术分類的估计和趋势分析

  • 下一代癌症诊断市场：按技术分類的差异分析
  • 次世代定序
  • qPCR，多重PCR
  • LOAC，RT-PCR
  • 蛋白质微阵列
  • DNA微阵列

第五章：下一代癌症诊断市场：按应用分類的估计和趋势分析

  • 下一代癌症诊断市场：按应用分類的波动分析
  • 生物标誌物开发
  • CTC分析
  • 蛋白质体分析
  • 表观遗传分析
  • 基因分析

第六章：下一代癌症诊断市场：按癌症类型分類的估计和趋势分析

  • 下一代癌症诊断市场：按癌症类型分類的波动分析
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 其他的

第七章 下一代癌症诊断市场：按功能分類的估计和趋势分析

  • 下一代癌症诊断市场：按功能分類的差异分析
  • 治疗监测
  • 伴随诊断
  • 预后
  • 癌症筛检
  • 风险分析

第八章：下一代癌症诊断市场：按地区分類的业务分析

  • 区域市场概览
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第九章 竞争情势

  • 公司分类
  • 策略规划
    • 新产品上市
    • 伙伴关係
    • 企业收购
    • 商业伙伴关係
    • 资金筹措
  • 主要企业市占率分析（2024 年）
  • 公司热力图分析
  • 公司简介
    • JANSSEN PHARMACEUTICALS, INC.
    • NOVARTIS AG
    • F. HOFFMANN-LA ROCHE LTD
    • KONINKLIJKE PHILIPS NV
    • ABBOTT
    • GE HEALTHCARE
    • THERMO FISHER SCIENTIFIC, INC.
    • AGILENT TECHNOLOGIES, INC.（DAKO）
    • ILLUMINA, INC.
    • QIAGEN
    • CEPHEID
    • OPKO HEALTH, INC.
    • HOLOGIC, INC（GEN-PROBE）
    • PERKINELMER INC.
    • SYSMEX
    • MYRIAD GENETICS, INC.
    • ALMAC GROUP
    • EXOSOME DIAGNOSTICS, INC.
    • GENOMIC HEALTH, INC.
Product Code: 978-1-68038-738-4

Next Generation Cancer Diagnostics Market Summary

The global next generation cancer diagnostics market size was valued at USD 16.61 billion in 2024 and is expected to reach USD 41.44 billion by 2033, growing at a CAGR of 11.15% from 2025 to 2033. The growth of the industry is anticipated to be driven by the rising incidence of oncology diseases, the need for efficient prognosis and early diagnosis of various forms of cancer, and rising initiatives by key players in the development of innovative solutions to meet the rising demand for efficient diagnostics.

Several tests, including physical examination, laboratory tests, imaging tests, and biopsy, have traditionally been performed in cancer diagnosis. Each step of the usual diagnostic procedure, with the prognosis and therapeutic decision made by oncologists, comes with a well-defined approach to avoid potential complications. This highlights the crucial importance of diagnosis throughout the entire oncology lifecycle, surpassing the therapeutic regimen's significance.

Next-generation sequencing (NGS) has become a transformative force in oncology diagnostics, enabling comprehensive genomic profiling of tumors to match patients with targeted therapies. By identifying actionable mutations and molecular alterations, NGS supports personalized medicine strategies that improve clinical outcomes. However, the impact of sequencing in routine care still requires clearer evidence stratification, as not all patients with actionable mutations ultimately receive targeted therapies. Barriers such as the timing of sequencing within the care pathway, physician interpretation, limited accessibility, and cost-effectiveness continue to restrict broader adoption.

Large-scale initiatives such as the TAPUR Study and the NCI MATCH Study aim to generate robust real-world evidence on the impact of sequencing-driven treatment selection. While CMS's National Coverage Determination expanded access by approving tests like FoundationOne CDx (F1CDx), the removal of the "coverage with evidence development" requirement has amplified calls for continuous outcome tracking, including metrics such as overall survival, progression-free survival, and response rates. Critics argue that broader panels (such as F1CDx) may add costs without always providing proportional clinical benefit, as illustrated by modest response rates in certain targeted therapy arms of NCI MATCH. This underscores the need for more evidence-based validation of sequencing-guided treatment approaches.

Beyond genomics, the field is rapidly expanding toward multi-omics integration. While DNA provides a static blueprint, complementary approaches such as RNA sequencing (transcriptomics) and proteomics (mass spectrometry) offer dynamic insights into gene expression and protein signaling pathways. Combined with metabolomics, these data layers create a holistic picture of tumor biology. Projects like TCGA have highlighted the promise of integrated-omics, though challenges remain in harmonizing these datasets into clinically actionable outputs.

At the same time, companies are accelerating the clinical deployment of such technologies. In May 2025, Illumina expanded its oncology portfolio with the launch of TruSight Oncology (TSO) Comprehensive, the first FDA-approved distributable CGP IVD kit with pan-cancer CDx claims, which is now reimbursed under Medicare and most commercial plans. The test, covering more than 500 genes, has also gained regulatory approval in Japan and is being integrated into clinical practice across community hospitals and academic centers. Illumina also deepened its partnership with Pillar Biosciences, adding the oncoReveal(R) CDx panel on the MiSeq Dx System, further democratizing access to in-house tumor profiling. Similarly, in June 2025, QIAGEN and Incyte entered a collaboration to develop a multimodal NGS companion diagnostic for myeloproliferative neoplasms, validated on the Illumina NextSeq 550Dx platform. The test will detect mutCALR mutations, supporting Incyte's innovative antibody program (INCA033989) for essential thrombocythemia and myelofibrosis. In March 2025, GenomOncology partnered with Chronetyx Laboratories to streamline clinical adoption by integrating its Pathology Workbench software with Chronetyx's FDA-cleared and CE-IVD-marked Cyx Solid Tumor 505 test, automating tertiary analysis and significantly reducing turnaround times for NGS results. Collectively, these initiatives highlight how leading players are addressing bottlenecks in reimbursement, workflow automation, and biomarker expansion to accelerate precision oncology adoption.

NGS also plays a central role in immuno-oncology diagnostics. Tumor mutational burden (TMB), PD-L1 expression, and neoantigen profiling are increasingly used as biomarkers for response to immune checkpoint inhibitors. Evidence from advanced hepatocellular carcinoma (HCC) shows that TP53 mutations correlate with improved survival, while TERT and BRD4 mutations signal poor prognosis. Exome sequencing combined with proteomics helps identify which neoantigens are presented by the major histocompatibility complex (MHC), guiding personalized immunotherapy strategies.

Emerging diagnostic modalities such as liquid biopsy and single-cell sequencing are further reshaping the market. Liquid biopsy offers a non-invasive method to detect circulating tumor DNA (ctDNA) and monitor treatment resistance in real-time. Meanwhile, single-cell sequencing reveals intratumoral heterogeneity, identifying subclones that may drive resistance or metastasis. Together, these technologies address key limitations of conventional tissue biopsies and are poised to drive faster adoption of precision oncology.

A powerful enabler of these advancements is the integration of artificial intelligence (AI) and machine learning (ML). These tools can mine vast NGS and multi-omics datasets, uncovering hidden correlations that inform predictive modeling, treatment selection, and resistance mechanisms. AI-enhanced bioinformatics pipelines are expected to improve diagnostic accuracy, reduce turnaround times, and optimize clinical decision-making, making them a critical growth driver for the next generation cancer diagnostics market.

Nevertheless, significant challenges remain. Not all mutations detected are actionable, and many fall into a gray zone with uncertain clinical utility. Ethical considerations around incidental findings, patient consent, and data privacy further complicate adoption. To maximize the potential of NGS and related technologies, standardized guidelines, stronger evidence frameworks, and multidisciplinary collaboration across oncologists, geneticists, bioinformaticians, and ethicists are essential.

Overall, the market is evolving from single-modality genomic profiling to integrated, AI-powered, multi-omics solutions. With advances such as Illumina's FDA-approved CGP assays, QIAGEN's hematology-focused companion diagnostics, and GenomOncology's workflow automation partnerships, alongside the broader adoption of liquid biopsy and immuno-oncology biomarkers, the sector is positioned for substantial growth. However, its long-term trajectory will hinge on demonstrating clear clinical utility, cost-effectiveness, and improved patient outcomes in real-world practice.

Global Next Generation Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global next generation cancer diagnostics market report based on technology, application, cancer type, function, and region:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Next Generation Sequencing
  • qPCR & Multiplexing
  • LOAC & RT-PCR
  • Protein Microarrays
  • DNA Microarrays
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Biomarker Development
  • CTC Analysis
  • Proteomic Analysis
  • Epigenetic Analysis
  • Genetic Analysis
  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others
  • Function Outlook (Revenue, USD Million, 2021 - 2033)
  • Therapeutic Monitoring
  • Companion Diagnostics
  • Prognostics
  • Cancer Screening
  • Risk Analysis
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Next Generation Cancer Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Technology Segment
      • 1.1.1.2. Application Segment
      • 1.1.1.3. Cancer Type Segment
      • 1.1.1.4. Function Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Next Generation Cancer Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Technology and Application Snapshot
  • 2.3. Cancer Type and Function Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Next Generation Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Exponentially decreasing cost of genetic sequencing
    • 3.4.2. Development of cluster chip technology and potential applications of CTC in cancer management
    • 3.4.3. Rising demand for preventive medicine & companion diagnostics
    • 3.4.4. Growing cancer incidence
  • 3.5. Market Restraint Analysis
    • 3.5.1. Requirement of expensive laboratory set-up for implementation of novel tests
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Next Generation Cancer Diagnostics Market: Technology Estimates & Trend Analysis

  • 4.1. Next Generation Cancer Diagnostics Market: Technology Movement Analysis
  • 4.2. Next Generation Sequencing
    • 4.2.1. Next Generation Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.3. qPCR & Multiplexing
    • 4.3.1. qPCR & Multiplexing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.4. LOAC & RT-PCR
    • 4.4.1. LOAC & RT-PCR Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Protein Microarrays
    • 4.5.1. Protein Microarrays Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.6. DNA Microarrays
    • 4.6.1. DNA Microarrays Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Next Generation Cancer Diagnostics Market: Application Estimates & Trend Analysis

  • 5.1. Next Generation Cancer Diagnostics Market: Application Movement Analysis
  • 5.2. Biomarker Development
    • 5.2.1. Biomarker Development Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. CTC Analysis
    • 5.3.1. CTC Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Proteomic Analysis
    • 5.4.1. Proteomic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Epigenetic Analysis
    • 5.5.1. Epigenetic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Genetic Analysis
    • 5.6.1. Genetic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Next Generation Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Next Generation Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 6.2. Lung Cancer
    • 6.2.1. Lung Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Breast Cancer
    • 6.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Colorectal Cancer
    • 6.4.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Cervical Cancer
    • 6.5.1. Cervical Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Next Generation Cancer Diagnostics Market: Function Estimates & Trend Analysis

  • 7.1. Next Generation Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 7.2. Therapeutic Monitoring
    • 7.2.1. Therapeutic Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Companion Diagnostics
    • 7.3.1. Companion Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Prognostics
    • 7.4.1. Prognostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Cancer Screening
    • 7.5.1. Cancer Screening Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Risk Analysis
    • 7.6.1. Risk Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Next Generation Cancer Diagnostics Market: Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Next Generation Cancer Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Scenario
      • 8.2.2.5. Competitive Scenario
    • 8.2.3. CANADA
      • 8.2.3.1. Canada Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Scenario
      • 8.2.3.5. Competitive Scenario
    • 8.2.4. MEXICO
      • 8.2.4.1. Mexico Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Scenario
      • 8.2.4.5. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Scenario
      • 8.3.2.5. Competitive Scenario
    • 8.3.3. GERMANY
      • 8.3.3.1. Germany Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Scenario
      • 8.3.3.5. Competitive Scenario
    • 8.3.4. SPAIN
      • 8.3.4.1. Spain Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Scenario
      • 8.3.4.5. Competitive Scenario
    • 8.3.5. FRANCE
      • 8.3.5.1. France Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Scenario
      • 8.3.5.5. Competitive Scenario
    • 8.3.6. ITALY
      • 8.3.6.1. Italy Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Scenario
      • 8.3.6.5. Competitive Scenario
    • 8.3.7. DENMARK
      • 8.3.7.1. Denmark Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Scenario
      • 8.3.7.5. Competitive Scenario
    • 8.3.8. SWEDEN
      • 8.3.8.1. Sweden Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Scenario
      • 8.3.8.5. Competitive Scenario
    • 8.3.9. NORWAY
      • 8.3.9.1. Norway Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Scenario
      • 8.3.9.5. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia-Pacific Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2. JAPAN
      • 8.4.2.1. Japan Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. Competitive Scenario
    • 8.4.3. CHINA
      • 8.4.3.1. China Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Competitive Scenario
    • 8.4.4. INDIA
      • 8.4.4.1. India Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Competitive Scenario
    • 8.4.5. SOUTH KOREA
      • 8.4.5.1. South Korea Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Scenario
      • 8.4.5.5. Competitive Scenario
    • 8.4.6. THAILAND
      • 8.4.6.1. Thailand Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Scenario
      • 8.4.6.5. Competitive Scenario
    • 8.4.7. AUSTRALIA
      • 8.4.7.1. Australia Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Scenario
      • 8.4.7.5. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2. BRAZIL
      • 8.5.2.1. Brazil Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.2.2. Key Country Dynamics
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. Competitive Scenario
    • 8.5.3. ARGENTINA
      • 8.5.3.1. Argentina Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.3.2. Key Country Dynamics
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2. SOUTH AFRICA
      • 8.6.2.1. South Africa Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Competitive Scenario
    • 8.6.3. SAUDI ARABIA
      • 8.6.3.1. Saudi Arabia Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. Competitive Scenario
    • 8.6.5. KUWAIT
      • 8.6.5.1. Kuwait Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. NEW PRODUCT LAUNCH
    • 9.2.2. PARTNERSHIPS
    • 9.2.3. ACQUISITION
    • 9.2.4. COLLABORATION
    • 9.2.5. FUNDING
  • 9.3. Key Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. JANSSEN PHARMACEUTICALS, INC.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. NOVARTIS AG
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. F. HOFFMANN-LA ROCHE LTD
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. KONINKLIJKE PHILIPS N.V.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. ABBOTT
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
    • 9.5.6. GE HEALTHCARE
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. THERMO FISHER SCIENTIFIC, INC.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. AGILENT TECHNOLOGIES, INC. (DAKO)
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. ILLUMINA, INC.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. QIAGEN
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. CEPHEID
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. OPKO HEALTH, INC.
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. HOLOGIC, INC (GEN-PROBE)
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives
    • 9.5.14. PERKINELMER INC.
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Financial Performance
      • 9.5.14.3. Product Benchmarking
      • 9.5.14.4. Strategic Initiatives
    • 9.5.15. SYSMEX
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Financial Performance
      • 9.5.15.3. Product Benchmarking
      • 9.5.15.4. Strategic Initiatives
    • 9.5.16. MYRIAD GENETICS, INC.
      • 9.5.16.1. Company Overview
      • 9.5.16.2. Financial Performance
      • 9.5.16.3. Product Benchmarking
      • 9.5.16.4. Strategic Initiatives
    • 9.5.17. ALMAC GROUP
      • 9.5.17.1. Company Overview
      • 9.5.17.2. Financial Performance
      • 9.5.17.3. Product Benchmarking
      • 9.5.17.4. Strategic Initiatives
    • 9.5.18. EXOSOME DIAGNOSTICS, INC.
      • 9.5.18.1. Company Overview
      • 9.5.18.2. Financial Performance
      • 9.5.18.3. Product Benchmarking
      • 9.5.18.4. Strategic Initiatives
    • 9.5.19. GENOMIC HEALTH, INC.
      • 9.5.19.1. Company Overview
      • 9.5.19.2. Financial Performance
      • 9.5.19.3. Product Benchmarking
      • 9.5.19.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 5 North America next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 6 North America next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 7 North America next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 8 U.S next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 9 U.S next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 10 U.S next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 11 U.S. next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 12 Canada next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 13 Canada next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 14 Canada next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 15 Canada next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 16 Europe next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 17 Europe next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 18 Europe next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 19 Europe next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 20 Europe next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 21 UK next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 22 UK next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 23 UK next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 24 UK next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 25 Germany next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 26 Germany next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 27 Germany next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 28 Germany next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 29 France next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 30 France next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 31 France next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 32 France next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 33 Italy next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 34 Italy next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 35 Italy next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 36 Italy next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 37 Spain next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 38 Spain next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 39 Spain next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 40 Spain next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 41 Denmark next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 42 Denmark next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 43 Denmark next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 44 Denmark next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 45 Sweden next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 46 Sweden next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 47 Sweden next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 48 Sweden next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 49 Norway next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 50 Norway next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 51 Norway next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 52 Norway next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 53 Asia Pacific next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 54 Asia Pacific next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 55 Asia Pacific next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 58 China next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 59 China next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 60 China next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 61 China next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 62 Japan next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 63 Japan next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 64 Japan next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 65 Japan next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 66 India next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 67 India next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 68 India next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 69 India next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 70 South Korea next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 71 South Korea next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 72 South Korea next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 73 South Korea next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 74 Australia next generation cancer diagnostics market, by technology 2021 - 2033 (USD Million)
  • Table 75 Australia next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 76 Australia next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 77 Australia next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 78 Thailand next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 79 Thailand next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 80 Thailand next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 81 Thailand next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 82 Latin America next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 83 Latin America next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 84 Latin America next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 85 Latin America next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 86 Latin America next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 87 Brazil next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 88 Brazil next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 89 Brazil next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 90 Brazil next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 91 Mexico next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 92 Mexico next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 93 Mexico next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 94 Mexico next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 95 Argentina next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 96 Argentina next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 97 Argentina next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 98 Argentina next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 99 Middle East & Africa next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 100 Middle East & Africa next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 101 Middle East & Africa next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 102 Middle East & Africa next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 103 Middle East & Africa next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 104 South Africa next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 105 South Africa next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 106 South Africa next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 107 South Africa next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 112 UAE next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 113 UAE next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 114 UAE next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 115 UAE next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 116 Kuwait next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 117 Kuwait next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 118 Kuwait next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 119 Kuwait next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global next generation cancer diagnostics market - Key market driver analysis
  • Fig. 7 Global next generation cancer diagnostics market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global next generation cancer diagnostics market - Porter's analysis
  • Fig. 10 Global next generation cancer diagnostics market - PESTEL analysis
  • Fig. 11 Global next generation cancer diagnostics market technology outlook key takeaways
  • Fig. 12 Global next generation cancer diagnostics market: Technology movement analysis
  • Fig. 13 Next generation sequencing market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 qPCR & multiplexing market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 LOAC & RT-PCR market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Protein microarrays market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 DNA microarrays market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Global next generation cancer diagnostics market application outlook key takeaways
  • Fig. 19 Global next generation cancer diagnostics market: application movement analysis
  • Fig. 20 Biomarker development market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 CTC analysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Proteomic analysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Epigenetic analysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Global next generation cancer diagnostics market cancer type outlook key takeaways
  • Fig. 25 Global next generation cancer diagnostics market: Cancer type movement analysis
  • Fig. 26 Lung cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Breast cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Colorectal cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Cervical cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Global next generation cancer diagnostics market function outlook key takeaways
  • Fig. 32 Global next generation cancer diagnostics market: Function movement analysis
  • Fig. 33 Therapeutic monitoring market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Companion diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 35 Prognostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Cancer screening market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Risk analysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Global next generation cancer diagnostics market: Regional movement analysis
  • Fig. 40 North America next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 42 Canada next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 44 UK next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 45 Germany next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 46 France next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 48 Italy next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 51 Norway next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 54 China next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 55 India next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 56 South Korea next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 58 Thailand next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 59 Latin America next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 60 Brazil next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 61 Mexico next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 62 Argentina next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 63 MEA next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 64 South Africa next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 65 Saudi Arabia next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 66 UAE next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 67 Kuwait next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 68 Strategy framework